Insight

Manni Mohyuddin: Why striving for MRD negativity at all costs and having MRD as a primary endpoint may not be ideal

Photo taken from Manni Mohyuddin/X

Feb 23, 2024, 14:39

Manni Mohyuddin: Why striving for MRD negativity at all costs and having MRD as a primary endpoint may not be ideal

Manni Mohyuddin, Assistant Professor at the Huntsman Cancer Institute at the University of Utah, shared on X/Twitter:

“Why striving for MRD negativity at all costs and having MRD as a primary endpoint may not be ideal:

In this randomized three-arm trial, the arm with the best MRD negativity rate had the worst overall survival!

One of the most important take-home messages from ASH23!

The pursuit of MRD negativity is neither necessary, nor safe for a substantial proportion of (older/less fit) patients with multiple myeloma, who experience prolonged disease control/excellent quality of life with lesser levels of response.

This is a fact that is often omitted from the discussion. Link to study.”

Source: Manni Mohyuddin/X

ASH23 cancer Huntsman Cancer Institute Manni Mohyuddin MRD MRD negativity multiple myeloma OncoDaily Oncology take-home messages from ASH23 University of Utah

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage